Products Affected - Description

• • Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 4 mL vial, 10 count, NDC 65219-0570-04
  • Bumetanide injection, Glenmark, 0.25 mg/mL, 10 mL vial, 10 count, NDC 68462-0470-54
  • Bumetanide injection, Glenmark, 0.25 mg/mL, 4 mL vial, 10 count, NDC 68462-0469-54
  • Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10
  • Bumetanide injection, Novadoz, 0.25 mg/mL, 10 mL vial, 10 count, NDC 72205-0102-07
  • Bumetanide injection, Sagent, 0.25 mg/mL, 4 mL vial, 10 count, NDC 70860-0405-04

Reason for the Shortage

• • Fresenius Kabi has bumetanide injection on shortage due to shipping delays.
  • Glenmark has bumetanide injection on shortage due to manufacturing delays.
  • Hikma has bumetanide injection on shortage due to increased demand.
  • Novadoz did not provide a reason for the shortage.
  • Pfizer has discontinued bumetanide injection in August 2022.
  • Sagent did not provide a reason for the shortage.

Available Products

• • Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 10 mL vial, 10 count, NDC 65219-0570-10
  • Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10
  • Bumetanide injection, Novadoz, 0.25 mg/mL, 4 mL vial, 10 count, NDC 72205-0101-07
  • Bumetanide injection, Sagent, 0.25 mg/mL, 10 mL vial, 10 count, NDC 70860-0406-10

• • Fresenius Kabi has bumetanide 0.25 mg/mL 4 mL vials on back order and the company estimates a release date of late-May 2024.
  • Hikma has bumetanide 0.25 mg/mL 10 mL vials on back order and the company estimates a release date of mid-May 2024.
  • Novadoz has bumetanide 0.25 mg/mL 10 mL vials on allocation.
  • Sagent has bumetanide 0.25 mg/mL 4 mL vials available on a limited allocation.
  • Glenmark has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of late-May 2024.